STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #955 by analyst upside · 2026-09-16
DFTX
Definium Therapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+93.8%
implied upside to consensus target
Current Price $36.82
Consensus Target $71.35
Bull Target $91.0
Bear Target $55.0
Analysts Covering 17
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
13
Hold
0
Sell
0
52-Week Low $8.77
52-Week High $49.7
YTD Return +169.9%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.77
52-Week High $49.7
Current Price $36.82
Bear Target $55.0
Bull Target $91.0
● Now $36.82 ● Target $71.35
TRADING DATA
Avg Volume 3.0M
YTD Return +169.9%
Analyst Count 17
Consensus Buy
Upside to Target +93.8%
Last Updated 2026-09-16

ANALYST SUMMARY

Definium Therapeutics, Inc. (DFTX) is currently trading at $36.82 with a Wall Street consensus price target of $71.35, implying potential upside of 93.8% over the next 12 months. 17 analysts currently cover DFTX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $91.0, while the most cautious has a target of $55.0.

DFTX operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 169.9% year-to-date and is currently trading near the upper end of its 52-week range of $8.77 – $49.7.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for DFTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital reit
Outperform → Outperform 2026-09-11 Building track record
B of A Securities ● Initiated
Buy 2026-08-18 Building track record
Maxim Group - Reiterated
Buy → Buy 2026-08-14 28% win rate (40 calls)
Jones Trading - Reiterated
Buy → Buy 2026-08-13 57% win rate (14 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-08-13 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-08-13 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-08-13 Building track record
Baird - Reiterated
Outperform → Outperform 2026-08-13 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
59
out of 100
Coverage depth
22/30
Consensus clarity
10/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →